These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25720792)

  • 21. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark.
    Olsen J; Jepsen MR
    Int J Technol Assess Health Care; 2010 Apr; 26(2):183-91. PubMed ID: 20392322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus vaccines: who will pay, who will receive, when to administer?
    Saslow D; Wheeler CM
    Ethn Dis; 2007; 17(2 Suppl 2):S2-8-13. PubMed ID: 17684807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey.
    King LA; Lévy-Bruhl D; O'Flanagan D; Bacci S; Lopalco PL; Kudjawu Y; Salmaso S;
    Euro Surveill; 2008 Aug; 13(33):. PubMed ID: 18761891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.
    Gertig DM; Brotherton JM; Saville M
    Sex Health; 2011 Jun; 8(2):171-8. PubMed ID: 21592430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey.
    Lévy-Bruhl D; Bousquet V; King LA; O'Flanagan D; Bacci S; Lopalco PL; Salmaso S;
    Eur J Cancer; 2009 Oct; 45(15):2709-13. PubMed ID: 19695863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vaccines against human papillomavirus (HPV); between registration and implementation].
    van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
    Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
    Slavkovsky R; Callen E; Pecenka C; Mvundura M
    Vaccine; 2024 Feb; 42(6):1200-1210. PubMed ID: 38302338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies.
    Ryser MD; McGoff K; Herzog DP; Sivakoff DJ; Myers ER
    Epidemics; 2015 Jun; 11():32-47. PubMed ID: 25979280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.
    Dunne EF; Flagg EW; Unger ER; Hsu K; Ghanen K; Kerndt P; Shlay JC; Koutsky LA; Datta DS; Panicker G; Zaidi A; Weinstock H; Markowitz LE
    Sex Transm Dis; 2014 Jan; 41(1):46-9. PubMed ID: 24326582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada.
    Drolet M; Deeks SL; Kliewer E; Musto G; Lambert P; Brisson M
    Vaccine; 2016 Apr; 34(16):1874-80. PubMed ID: 26954465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bug breakfast in the bulletin: the early impact of the national HPV vaccination program.
    Quinn E; Donovan B; Sheppeard VK
    N S W Public Health Bull; 2012 Dec; 23(9-10):208. PubMed ID: 23442998
    [No Abstract]   [Full Text] [Related]  

  • 35. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical cancer screening in Europe: Quality assurance and organisation of programmes.
    Elfström KM; Arnheim-Dahlström L; von Karsa L; Dillner J
    Eur J Cancer; 2015 May; 51(8):950-68. PubMed ID: 25817010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents.
    Choi HC; Leung GM; Woo PP; Jit M; Wu JT
    Vaccine; 2013 Dec; 32(1):78-84. PubMed ID: 24188759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.
    Wong LP; Han L; Li H; Zhao J; Zhao Q; Zimet GD
    Hum Vaccin Immunother; 2019; 15(7-8):1533-1540. PubMed ID: 31017500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs.
    Khan K; Curtis CR; Ekwueme DU; Stokley S; Walker C; Roland K; Benard V; Saraiya M
    Cancer; 2008 Nov; 113(10 Suppl):3004-12. PubMed ID: 18980296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.